Skip to main content
Caplight Logo









Gero

Gero

Private
SingaporeHealthcare & Life Scienceshttps://www.gero.ai/

Last Round

Series A

Jun 17, 2026

Total Funding Raised

$34M

Momentum

Top 10%

of companies Caplight tracks

Company Overview

Gero is a biotechnology company that utilizes a physics-informed artificial intelligence platform to analyze real-world human health data for the discovery of novel therapeutics targeting aging and chronic diseases.

Sector

Healthcare & Life Sciences

Verticals

Drug Discovery, Biotechnology, Medical AI, Healthcare Analytics

Business Model

B2B

Customer Profile

Services & Consulting, Revenue Share

AI Layer

Foundation

Keywords

drug discoveryAI drug discoverybiotech AIlongevity researchtherapeutic target identificationlarge health modelsin silico drug discoveryage-related diseasesgenerative biologymulti-omics datapreclinical researchtarget discoverybiotech platformdrug pipeline

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Gero Comparables

Compare Gero with similar companies based on industry and business-model similarity.

Gero comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Turbine
83%
Fountain Therapeutics
82%
Integrated Biosciences
81%

Gero Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AJun 17, 2026
Series A ExtensionOct 18, 2023
Series AAug 4, 2020
SeedMay 1, 2019

Key People

Founding team and executive leadership

Peter Fedichev

Co-founder & CEO

Founding Team

Alexey Lyapin

Chief Financial Officer

Executive Team

Aleksandr Sviridov

Chief Operating Officer

Executive Team

Gero Investors

Notable investors and investment history

Gero investors
InvestorRounds
TOP VentureSeries A
VitaDAOSeries A Extension
Melnichek InvestmentsSeries A, Series A Extension
Bulba VenturesSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jun 17, 2026

    $17M raised with participation from Leonid Lozner and Melnichek Investments.

  • Jul 14, 2025

    Brian Kennedy appointed to the Board of Directors.

Gero Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Gero Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Gero's valuation, stock price, and market status.

Firmographic Details

HeadquartersSingapore
Employee Range136
Year Founded2018
Last FundingJun 17, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?